EUVIMEDEUVIMED entdecken
Crossref

The Evolving Role of High‐Sensitivity C‐Reactive Protein for Mortality Prediction Across the Spectrum of Cardiovascular–Kidney–Metabolic Syndrome

Jing Li, Shuohua Chen, Xiaoli Zhang, Xue Xia iD, Yuxiang Yan iD, Shouling Wu, Anxin Wang iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Jing Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: C-Reactive Protein, Metabolic Syndrome, Cardio-Renal Syndrome, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Outstanding Young Investigator Program of Capital Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

High‐sensitivity C‐reactive protein (hsCRP) is central to cardiovascular–kidney–metabolic (CKM) syndrome pathogenesis, but its prognostic value across progressive CKM stages remains uncertain. We aimed to evaluate the stage‐specific associations between hsCRP and mortality in CKM syndrome. Materials and Methods In this prospective analysis of 86 829 participants from the Kailuan Study, we evaluated hsCRP's association with all‐cause mortality stratified by AHA‐defined CKM stages (0–4). Multivariable Cox models assessed hazard ratios (HRs) for mortality per unit increase in ln(hsCRP) and by dichotomised hsCRP (< 2 vs. ≥ 2 mg/L).

Results

Over a median follow‐up of 16.01 years, 13 960 deaths occurred. HsCRP levels were associated with higher mortality across all stages, but the association progressively attenuated with advancing CKM stages. Adjusted HRs per ln(hsCRP) were 1.11 (95% CI: 1.03–1.20) in Stage 0, 1.14 (1.07–1.21) in Stage 1, 1.08 (1.06–1.10) in Stage 2, 1.05 (1.03–1.07) in Stage 3 and 1.04 (1.00–1.08) in Stage 4 ( p for interaction < 0.001). Similarly, dichotomised hsCRP showed declining mortality risks from Stage 0 (HR: 1.51, 1.15–1.98) to Stage 4 (HR: 1.07, 0.97–1.19). Restricted cubic splines confirmed this gradient, with early stages displaying steep risk curves that plateaued in advanced stages. Sensitivity analyses supported robustness.

Conclusions

The association of hsCRP with mortality diminishes with CKM syndrome progression, suggesting a shift from inflammation‐driven risk in early stages to complex multiorgan dysfunction in late stages. These findings advocate for stage‐specific risk assessment, with hsCRP retaining utility in early CKM management but requiring integrated approaches in advanced disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

C-Reactive ProteinMetabolic SyndromeCardio-Renal SyndromeCardiovascular DiseasesHumansFemaleMaleProspective StudiesPrognosisMiddle AgedBiomarkersAgedPredictive Value of TestsChinaRisk Factors

Stichwörter der Autor:innen

cardiovascular–kidney–metabolic syndromecohorthigh‐sensitivity C‐reactive proteinmortality

Substanzen

C-Reactive ProteinBiomarkers

Autor:innen und Institutionen

  • Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Department of Clinical Epidemiology and Clinical Trial, Capital Medical University, Beijing, China.
  • Department of Epidemiology and Biostatistics, School of Public Health, Capital Medical University, Beijing, China.
  • Department of Cardiology, Kailuan General Hospital, North China University of Science and Technology, Tangshan, Hebei, China.

ORCID-Profile: Xue Xia, Yuxiang Yan, Anxin Wang

Förderung

  • Outstanding Young Investigator Program of Capital Medical University

Zitieren

APA

Li, J., Chen, S., Zhang, X., Xia, X., Yan, Y., Wu, S., & Wang, A. (2026). The Evolving Role of High‐Sensitivity C‐Reactive Protein for Mortality Prediction Across the Spectrum of Cardiovascular–Kidney–Metabolic Syndrome. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70843

Vancouver

Li J, Chen S, Zhang X, Xia X, Yan Y, Wu S, et al. The Evolving Role of High‐Sensitivity C‐Reactive Protein for Mortality Prediction Across the Spectrum of Cardiovascular–Kidney–Metabolic Syndrome. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70843

BibTeX
@article{Li2026,
  author = {Li, Jing and Chen, Shuohua and Zhang, Xiaoli and Xia, Xue and Yan, Yuxiang and Wu, Shouling and Wang, Anxin},
  title = {The Evolving Role of High‐Sensitivity C‐Reactive Protein for Mortality Prediction Across the Spectrum of Cardiovascular–Kidney–Metabolic Syndrome},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70843}
}
Kostenlos starten →